Diabetes risk after pancreatic cancer surgery
Official title: Prospective Cohort Study on Endo-Exdo Secretory Function Alterations and All-round Outcomes After Pancreatic Cancer
Run by Shanghai Changzheng Hospital · NCT06585072 · Data updated 2026-11-12
This tests how often adults without prior diabetes develop pre-diabetes or diabetes after pancreatic cancer surgery and whether changes in pancreatic hormone and enzyme function affect recovery and overall outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Shanghai Changzheng Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | January 3, 2025 |
| Main results expected | September 1, 2026 |
| Study ends | September 1, 2026 |
| Registry record updated | July 1, 2025 |
| Trial ID | NCT06585072 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with pancreatic cancer scheduled for pancreatectomy at Shanghai Changzheng Hospital who do not have prior diabetes and who can provide informed consent are ideal candidates.
✕Probably not a fit
Patients with pre-existing diabetes or pre-diabetes, positive islet autoantibodies, secondary diabetes risk factors, pregnant or nursing women, or those unable to consent are excluded and are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational cohort of adults undergoing pancreatectomy at Shanghai Changzheng Hospital, with standardized perioperative care and banked serum and pathology samples. Enrolled participants who do not have pre-existing diabetes undergo continuous peripheral blood glucose monitoring to capture incident pre-diabetes and diabetes. The study will compare rates of new glucose metabolic disorders across different pancreatic disease etiologies and surgical procedures. It will also examine whether changes in endocrine and exocrine pancreatic function after surgery are linked to overall clinical outcomes.
Why it matters
Potential benefit: If successful, this could identify patients at higher risk of developing new-onset glucose disorders after pancreatic surgery and inform targeted monitoring and early treatment to reduce complications.
How similar studies have gone: Previous observational work has documented new-onset diabetes after pancreatic resection and suggested links between endocrine/exocrine changes and outcomes, but results vary and prospective, standardized data collection like this remains relatively common rather than novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. male or female Chinese subjects; 2. Age ≥ 18 years; 3. patients with pancreatic cancer who are proposed to undergo pancreatectomy by pancreaticobiliary surgery at our hospital; 4. those who voluntarily completed the Pancreatobiliary Surgery Cohort Study and signed the informed consent; 5. those who have completed and banked serum and pathological specimens at our hospital. \- Exclusion Criteria: 1\. those with a previous history of comorbid diabetes mellitus or pre-diabetes mellitus, or preoperative HbA1C ≥ 6.0% or fasting blood glucose ≥ 6.1 mmol/l; 2. those with positive islet-associated antibodies 3. those with the presence of medications, endocrine disease exposures that can lead to a risk of secondary diabetes; 4. pregnant or nursing women; 5. Cognitive impairment or other reasons for failing to sign the informed consent form. \-
Where it's running
-
Changzheng Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Tuo Li, Doctor
- Email: dr.lituo@smmu.edu.cn
- Phone: 86-13918507887
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Screening for pancreatic cancer in people with new or worsening diabetes
This study is testing if people over 50 with new or worsening diabetes might have pancreatic cancer and will use imaging and blood samples to look for early signs of the disease.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer
This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.
-
Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer
This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.